Open AccessCalcitriol enhances pyrazinamide treatment of murine tuberculosis
Author(s) -
Jing Zhang,
Ming Guo,
Zhixiang Huang,
Rong Bao,
Yu Qian,
Ming Dai,
Xin Wang,
Rong Yan
Publication year - 2019
Publication title -
chinese medical journal/chinese medical journal
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000394
Subject(s) - pyrazinamide , tuberculosis , mycobacterium tuberculosis , medicine , calcitriol , pharmacology , in vivo , cathelicidin , vitamin d and neurology , immunology , ethambutol , microbiology and biotechnology , immune system , biology , pathology , innate immune system
Tuberculosis is a leading cause of morbidity and mortality in humans worldwide. There is an urgent need for new and effective drugs to treat tuberculosis and shorten the duration of tuberculosis therapy. 1, 25-dihydroxy vitamin D3 (1,25 (OH)2D3) has been reported to have a synergistic effect with pyrazinamide (PZA) in killing tubercle bacilli in vitro. The addition of 1,25 (OH)2D3 to standard tuberculosis treatment should benefit patients if the adjunctive drug has a synergistic effect in vivo. Thus, in this study, calcitriol (bioactive 1,25 (OH)2D3) was administered to mice undergoing treatment for Mycobacterium tuberculosis (M.tb) infection with PZA, a first-line anti-tuberculosis drug, to determine whether vitamin D3 enhances the therapeutic effect.